Back to the Xenexus Pharmaceutical Home Page


Xenexus Pharmaceuticals - Developing innovative drugs for the treatment of neurological disorders Xenexus Pharmaceuticals - Developing innovative drugs for the treatment of neurological disorders Xenexus Pharmaceuticals - Developing innovative drugs for the treatment of neurological disorders Xenexus Pharmaceuticals - Developing innovative drugs for the treatment of neurological disorders

Management

Dr Michael L. Selley, FRACI

Chairman and Chief Executive Officer


Dr Michael L. Selley - Chairman and Chief Executive Officer

Dr Selley has considerable experience in pharmaceutical research and development. He was the founder and Chief Scientific Officer of Nuon Therapeutics, Inc., the founder of Xenexus Pharmaceuticals Pty. Ltd and a cofounder of Cherwell Therapeutics Ltd. Dr Selley served as Chief of Staff to the Minister for Science and Technology in the Parliament of Australia and held academic appointments at the John Curtin School of Medical Research in the Institute of Advanced Studies at the Australian National University. He has worked in the international pharmaceutical industry in a number of roles, including drug discovery, pharmacology, toxicology, and clinical trials.

Board of Directors

Prof. Sir Marc Feldmann, FMedSci, FAA, FRS

Prof. Marc Feldmann was formally Professor and Director of the Kennedy Institute of Rheumatology at the University of Oxford. Prof. Feldmann, together with his collaborator, Prof. Ravinder Maini, was awarded the Crafoord Prize in 2000 and the Albert Lasker Award for Clinical Medical Research in 2003 for their discovery that anti-TNF therapy was an effective treatment for rheumatoid arthritis. Prof. Feldmann was European Inventor of the Year in the lifetime achievement category and was awarded the John Curtin Medal of the Australian National University in 2007. In 2008 Prof. Feldmann and Prof. Maini were awarded the Dr Paul Janssen Award for Biomedical Research. They were awarded the Ernst Schering Prize in 2010 and the Canada Gairdner International Award in 2014.

Dr Michael L. Selley

See biography above

Scientific Advisers

Prof. Scott L. Friedman, M.D.

Prof. Scott L. Friedman, M.D., is Fishberg Professor of Medicine, Professor of Pharmacology and Systems Therapeutics, Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai Hospital, New York. Prof. Friedman is responsible for the discovery of a novel tumour suppressor gene, KLF6 that is inactivated in a number of human cancers, including primary liver cancer. He has performed pioneering research into the underlying causes of scarring, or fibrosis, associated with chronic liver disease, which affects millions worldwide. He was among the first to isolate and characterise the hepatic stellate cell, which is the key cell type responsible for scar production in liver.






by Echidna Web Design. Click here to visit.